wuxi apptec

WuXi STA Opens Nucleic Acid Drug Manufacturing Facility

Nucleic acid drugs have the potential to treat neuromuscular and metabolic diseases where small molecule drugs have failed.

WuXi AppTec And BioSolveIT Set Up Molecule Library

The GalaXi® platform grants researchers access to billions of virtual molecules, paving the way for faster drug discovery and development.

WuXi AppTec Acquires US-Based Pharmapace

Pharmapace will become a wholly-owned subsidiary of WuXi Clinical and will continue to focus on growing its core biometrics competences.

WuXi STA And BioLingus Partner On Drug Delivery

The collaboration leverages BioLingus' platform for stabilizing and delivering drugs via tissues under the tongue.

WuXi And CECD Join Forces To Create Big Data Solutions For Healthcare

The joint venture will use big data, cloud computing and artificial intelligence to advance research in healthcare and pharmaceuticals.

WuXi AppTec Launches Drug Screening Library

The DNA-Encoded Library platform consists of 80 billion unique molecules which are structurally diverse and chemically exclusive.

WuXi STA’s Facility Passes Fourth US FDA Inspection

The Jinshan facility is equipped with more than 100 modern reactors for drug manufacturing and houses industry-leading technology platforms for flow chemistry and biocatalysis.

WuXi STA And Antengene To Collaborate On Cancer Drug Development

Antengene is tapping on WuXi STA’s end-to-end drug development platform to accelerate the clinical testing and commercialization of cancer drugs.

WuXi STA Builds A New R&D Center In Shanghai

The new R&D center in Shanghai, China, will enable drug developers to accelerate their projects from preclinical to commercial stage.

JW Therapeutics Raises US$90 Million In Series A Funding Round

The funds will be used to further advance JW Therapeutic's chimeric antigen receptor T-cell clinical program, develop a therapeutic pipeline and build a new commercial manufacturing facility.